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Network meta-analysis (NMA) combines direct and indirect evidence from trials
to calculate and rank treatment estimates. While modelling approaches for contin-
uous and binary outcomes are relatively well developed, less work has been done
with time-to-event outcomes. Such outcomes are usually analysed using Cox pro-
portional hazard (PH) models. However, in oncology with longer follow-up time,
and time-dependent effects of targeted treatments, this may no longer be appropri-
ate. Network meta-analysis conducted in the Bayesian setting has been increasing
in popularity. However, fitting the Cox model is computationally intensive, making
it unsuitable for many datasets. Royston-Parmar models are a flexible alternative
that can accommodate time-dependent effects. Motivated by individual participant
data (IPD) from 37 cervical cancer trials (5922 women) comparing surgery, radio-
therapy, and chemotherapy, this paper develops an IPD Royston-Parmar Bayesian
NMA model for overall survival. We give WinBUGS code for the model. We show
how including a treatment-ln(time) interaction can be used to conduct a global
test for PH, illustrate how to test for consistency of direct and indirect evidence,
and assess within-design heterogeneity. Our approach provides a computationally
practical, flexible Bayesian approach to NMA of IPD survival data, which readily
extends to include additional complexities, such as non-PH, increasingly found in
oncology trials.
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1 INTRODUCTION
Network meta-analysis (NMA) is the extension of pairwise
meta-analysis (MA) to a network of clinical trials in which
each trial compares at least 2 treatments from a set of treat-
ments in a specific disease area. Network meta-analysis uses
a single statistical model to combine both direct and indirect
evidence from all of the trials in a network to calculate treat-
ment effect estimates for every treatment comparison, regard-
less of whether 2 treatments have been compared directly, and
thus permits ranking of the treatments.
Most NMA methods have developed as a result of extend-
ing MA methods for 2 treatments to 3 or more treatments
to take advantage of the indirect evidence. Modelling
approaches for continuous and binary outcomes are rela-
tively well developed, but less work has been done with
time-to-event outcomes. Such outcomes have usually been
analysed using semiparametric Cox proportional hazard (PH)
models,1 but in oncology with longer follow-up of trials, and
time-dependent effects of targeted treatments, we are see-
ing increasing evidence of non-PH so this may no longer be
appropriate.2,3
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Network meta-analysis can be conducted using individ-
ual participant data (IPD) or aggregate data (AD) with IPD
considered the gold standard for both MA and NMA.4 Indi-
vidual participant data allows trials to be re-analysed in a
consistent manner standardising inclusion and exclusion cri-
teria, re-coding covariates, including previously excluded
patients and using up-to-date follow-up information. Data can
be checked against the published results to ensure the quality
of randomisation and follow-up.4 Most importantly, IPD pro-
vides greater statistical power for subgroup analyses, enables
the analysis of patient level covariates, and is essential for
investigating interactions between treatment and patient level
covariates.5,6
Network meta-analysis conducted in the Bayesian set-
ting has been increasing in popularity in recent years.7 The
Bayesian framework naturally handles random effects, avoid-
ing awkward numerical integration. In particular, Crowther
et al8 reported that—when the number of trials in the MA is
small—maximum likelihood tends to underestimate random
effect variances, and this issue is alleviated with a Bayesian
analysis (albeit at the expense of some overestimation of
the variances). Other attractions include ready inference for
treatments never compared directly, easy assessment of net-
work consistency, a natural ranking method, which allows
calculation of cumulative rankings to determine the prob-
ability of a treatment being 1 of the top 3 most effective
treatments, and the ability to adjust for correlations that
arise from the inclusion of multiarm trials.9-11 Another poten-
tial advantage of the Bayesian approach is that, if we wish
to extend the models by adjusting for patient level covari-
ates, then a Bayesian model can readily incorporate the
imputation of any missing values (Carpenter and Kenward12,
p. 47). Bayesian inference also provides a natural framework
for prediction.13
Bayesian NMA models are commonly fitted in WinBUGS.
However, fitting the Cox PH model in the Bayesian setting
is computationally intensive, as each individual's data have
to be repeated for each risk set they belong to. This makes
it extremely cumbersome even for moderately sized datasets,
such as our motivating cervical cancer data described below.
Therefore, alternative methods for time-to-event data are
needed.
Crowther proposed 2 alternatives to the Cox model for
time-to-event outcomes, which could be used for MA.8,14
First, a one-step IPD MA using a Poisson generalised lin-
ear model (GLM), which could be implemented with fixed
or random effects and with baseline hazard stratified by
trial. This model was extended to include treatment-covariate
interactions and to allow non-PH of the treatment effects.14
Crowther et al14 demonstrated the use of Poisson GLM in
both the frequentist and Bayesian settings. To fit a Poisson
GLMwith time-to-event data, the time scale must be split into
intervals.14 A substantial number of intervals may be required
in applications, and their location and length may be
important.15(p65) Royston and Lambert further comment (p90)
on the potential computational issues with the piecewise
exponential approach with large datasets. For example, when
fitting the piecewise hazard model in WinBUGS, the data for
patients in the risk set at the beginning of each interval need
to be repeated. Assessing and modelling non-PH is also rela-
tively complex using this approach relative to a spline-based
approach (see Subsection 4.1.1).
By contrast, Royston and Lambert (p78) find that (pro-
vided the log cumulative hazard is modelled) the precise
knot location is relatively unimportant. These points, along-
side the flexibility of splines, motivated Crowther et al8 to
develop maximum likelihood approaches for random effect
models with splines, using Gauss-Hermite quadrature for the
numerical integration. However, maximum likelihood meth-
ods become increasingly challenging as the number of ran-
dom effects increase and may also struggle when the number
of trials in an MA is small.8,15
In this context, Jansen16,17 explored using fractional
polynomials18 to model the baseline hazard in two-step
random effects NMA of IPD time-to-event data. This
work and the work of Ouwens19 were extended to include
treatment-covariate interactions, which allowed the model to
adjust for confounding.17 However, fractional polynomials
can result in unexpected end effects. Specifically, the shape
of a fractional polynomial at each end of the dataset, where
there is often less information, may be unduly influenced by
what happens in the middle of the dataset.
In the light of this, we concluded that the Royston-Parmar
model,20 with the baseline log-cumulative hazard modelled
by restricted cubic splines (RCSs), is a natural way forward.
The complexity and flexibility of the model are determined
by the degrees of freedom of the RCS. Restricted cubic
splines have the advantage over fractional polynomials that
they are linear at each end, and so reduce the possibility of
undesirable end effects. They are therefore more likely to pro-
vide a flexible yet robust approach, appropriate for trials in
most networks.
Further, as we show below, such models can be readily fit-
ted in WinBUGS,21 but without the need to expand the data.
For networks containing many thousands of patients, this is a
key practical advantage.
Therefore, in this paper, we bring together the flexibility of
Bayesian modelling and the Royston-Parmar model, describ-
ing a one-step IPD NMA of time-to-event data to a network
of clinical trials in cervical cancer. We show how includ-
ing a treatment-ln(time) interaction can be used to conduct
a global test for PH, illustrate how we can test for consis-
tency of direct and indirect evidence, and assess within design
heterogeneity (ie, heterogeneity between trials of the same
design). We give commented WinBUGS code for fitting the
model. Network meta-analysis combines direct randomised
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evidence with indirect evidence, and this combination essen-
tially relies on the external validity of the direct evidence.
When presenting the results, we therefore propose and illus-
trate, presenting the direct and indirect treatment estimates
alongside the combined estimate.
The paper is structured as follows. We start by describ-
ing our dataset in Section 2. In Section 3, we review the
Royston-Parmar model and apply it to the MA setting before
extending it to the NMA setting in Section 4. In Section 5, the
Royston-Parmar NMA model is applied to the cervical can-
cer dataset with annotated code implementing our approach
provided in Appendix A. We conclude with a discussion in
Section 6.
2 CERVICAL CANCER DATA
Our motivating data come from 3 meta-analyses of
randomised controlled trials (RCTs) in cervical cancer per-
formed by the Chemoradiotherapy for Cervical Cancer Meta-
Analysis Collaboration22 and the Neoadjuvant Chemotherapy
for Cervical Cancer Meta-Analysis Collaboration.23 The 3
meta-analyses considered 4 different treatments: radiotherapy
(RT), chemoradiation (CTRT), neoadjuvant chemotherapy
plus radiotherapy (CT+RT), and neoadjuvant chemother-
apy plus surgery (CT+S) using 4 different designs: RT vs
CTRT (18 trials), RT vs CT+RT (16 trials), RT vs CT+S
(5 trials), and RT vs CT+RT vs CT+S (2 trials) (Figure 1).
The Neoadjuvant Chemotherapy for Cervical Cancer
Meta-Analysis Collaboration23 conducted one systematic
review to consider 2 related but separate treatment compar-
isons: RT vs CT+RT and RT vs CT+S. Trial accrual periods
ranged from 1982 to 1999. The Chemoradiotherapy for Cer-
vical Cancer Meta-Analysis Collaboration22 conducted one
systematic review to compare RT and CTRT. Trial accrual
periods ranged from 1987 to 2006. Both systematic reviews
were completed following detailed prespecified protocols.
The RT vs CTRT comparison included a total of 18 RCTs
and 4818 patients. In the original publication, 5 of these trials
were excluded from the main analysis, as patients on at least
one of the treatment arms received additional treatment. This
resulted in a subset of 13 trials (3104 patients), which were
identified and used for the main analysis. Within this subset
of 13 trials 2 three-arm trials combined 2 different forms of
CTRT and compared them with a single control arm and 3
4-arm trials were split into 2 unconfounded comparisons of
RT vs CTRT for analysis as separate trials. This resulted in
16 trials included in the main analysis. As in the original pub-
lication, the data will be treated in the same way throughout
this paper.
Across the 3 meta-analyses that form our network of trials,
overall survival data were available for 5922 patients from 37
RCTs (35 two-arm RCTs, 2 three-arm RCTs).
FIGURE 1 Cervical cancer network diagram. Node size and edge thickness are proportional to the number of studies involved in each direct
comparison. RT, radiotherapy; CTRT, chemoradiation, CT+RT, neoadjuvant chemotherapy plus radiotherapy; CT+S, neoadjuvant chemotherapy
plus surgery. NB: the numbers for each treatment arm do not add up to the total number of patients included in the network as multiarm patients are
counted twice. There are a total of 37 trials in this network; however, in the figure, the 2 multiarm trials are counted 3 times each as they are included
in the number of trials for each pairwise comparison. Arrows denote direction of treatment comparison in NMA models
(see Section 4.1)
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3 REVIEW OF THE
ROYSTON-PARMAR MODEL
AND IMPLEMENTATION
OF PAIRWISE META-ANALYSIS
METHODS
3.1 Royston-Parmar model for the log
cumulative hazard rate
To implement the Royston-Parmar model in the NMA set-
ting, we use an RCS to model the log baseline cumulative
hazard rate for each trial. An RCS is a piecewise polynomial
with additional constraints to ensure a smooth log baseline
cumulative hazard. An RCS has a number of interior knots
as well as boundary knots at the minimum and maximum of
the uncensored survival times. The fitted RCS is continuous,
has continuous first and second derivatives, and is forced to
be linear before the first knot and after the last knot.24 Fur-
ther details on RCS can be found in Lambert and Royston,24
Royston and Parmar,20 and Royston and Lambert.15
The spline function for patient i in trial j with p interior
knots can be written as
sj
(
ln(ti)
)
= 𝛾1 + 𝛾2u0
(
ln(ti)
)
+ 𝛾3u1
(
ln(ti)
)
+ · · · + 𝛾p+2up
(
ln(ti)
)
,
(1)
where ln(ti) is the natural logarithm of event time for patient
i, u0
(
ln(ti)
)
, u1
(
ln(ti)
)
, … , up
(
ln(ti)
)
are the orthogonalised
basis functions and the 𝛾 's their coefficients. Basis functions
are defined in Appendix A.
The RCS for the log cumulative hazard can be incorpo-
rated into a PH flexible parametric model with xi the treatment
indicator for patient i and 𝛽 the coefficient,
log{H(t|xi)} = 𝜂ij = sj( ln(ti)) + 𝛽xi. (2)
Covariates can also be included in (2) as adjustment factors
if necessary. To fit this flexible parametric model (2), the log
likelihood of the observed data must be calculated. To derive
the log likelihood, the derivative of 𝜂ij is required,
d𝜂ij = 𝛾2du0
(
ln(ti)
)
+ 𝛾3du1
(
ln(ti)
)
+ · · · + 𝛾p+2dup
(
ln(ti)
)
,
(3)
where dup is the derivative with respect to ln(ti) of up.
The likelihood lij for patient i is then
log(lij) =
{
log(d𝜂ij) + 𝜂ij − exp(𝜂ij) for an observed event,
− exp(𝜂ij) for a censored observation.
(4)
WinBUGS can be used for Bayesian inference with this
likelihood. WinBUGS does not have an appropriate inbuilt
distribution for the Royston-Parmar model; therefore, the
“zeros trick” is required to enable a general likelihood to be
specified.15 The probability density function of the Poisson
distribution is f (y|𝜆) = 𝜆y exp(−𝜆)
y!
. The “zeros trick” works
because when y is set equal to zero, the Poisson likelihood
is exp(−𝜆). Therefore, if we set 𝜆 equal to the negative log
likelihood contribution for each patient and we use a psuedo
observation “y = 0” for each patient, using a Poisson model
gives us the correct likelihood.15 As a Bayesian approach,
WinBUGS has the added advantage of the flexibility to extend
models (eg, to include multiple random effects and covari-
ates) without involving numerical integration. Then, the fixed
effect of treatment in (2) can be readily replaced by a random
effect if desired.
3.1.1 Testing for non-PHs
Non-PH can be assessed by including a treatment-ln(time)
interaction in (2):
ln{H(t|xij)} = sj( ln(ti)) + 𝛽xi + 𝛼xi (ln (ti)) , (5)
where xi (ln (ti)) is the treatment-ln(time) interaction term for
patient i and 𝛼 the coefficient. In (3), the derivative of (2) is
calculated with respect to ln(t); therefore, (3) must be updated
appropriately when we include treatment-ln(time) interac-
tions. A further extension is to allow 𝛼 to be random across
(groups of) trials; see Section 4.1.1. If the treatment-ln(time)
interaction term is statistically significant, then there is evi-
dence of non-PH in the pairwise comparison. If this is the
case, then a treatment-ln(time) interaction for this pairwise
comparison should be included in the NMA model.
Before conducting MA or NMA, each trial should be
assessed individually for evidence of non-PH. A natural way
to do this is to calculate the Schoenfeld residuals, which can
be examined graphically and formally tested for nonpropor-
tionality using a 𝜒2 test. As each trial is independent of each
other, in each MA, if desired, we can add up the values of
the 𝜒2 statistics to provide an overall nonspecific test with
degrees of freedom equal to the number of trials in the MA.
The Schoenfeld residual test, applied to each trial in turn,
looks for any evidence of a different trend in the Schoenfeld
residuals between the treatment groups.25 It highlights any
trials that show a marked departure from PH, which should
be investigated further before including the trial in a PH
NMA. Such departures may be due to quirks of the design
or follow-up. By contrast, testing the null hypothesis that
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𝛼 = 0 in (5) provides a more powerful test of the specific
hypothesis that the log-cumulative hazard has a different lin-
ear trend in log(t) in the different treatment groups. If, across
the (N)MA, we reject 𝛼 = 0, then summarising treatment
effects by a single hazard ratio is inappropriate.
3.2 Estimation
To fit the Royston-Parmar model in WinBUGS, the basis
functions for the RCS must be calculated and then orthog-
onalised using Gram-Schmidt orthogonalisation. The basis
functions can be calculated in Stata or any other statistical
software package. Full details on this process are provided in
Appendix A and Lambert and Royston.24
Once calculated, the basis functions are passed to Win-
BUGS to fit the one-step NMA model (6) in which the
logarithm of the baseline cumulative hazard function is mod-
elled as a “natural” cubic spline function of log time.20 The
default knot locations for RCS are based on centiles of the
uncensored survival times with additional boundary knots
placed at the minimum and maximum values of the uncen-
sored survival times. Royston and Lambert do not recommend
models with more than 3 knots, as the resulting curves can be
unstable; however, they do acknowledge that in larger datasets
a larger number of knots may be required.15 It has been shown
recently that parameter estimates are generally robust to knot
locations26; however, it is also possible to choose knot loca-
tions. With the cervical cancer data, we chose our own knot
locations because we wanted to ensure that the log cumulative
hazard resulting from the WinBUGS model was as similar to
the nonparametric Nelson-Aalen estimate of the log cumula-
tive hazard as possible for each trial. Starting with the default
knot locations, we plotted the log cumulative hazard resulting
from the WinBUGS model with 1, 2, and 3 knots against log
time alongside the Nelson-Aalen estimate of the log cumula-
tive hazard and its 95% confidence intervals. For each trial,
we chose the model with the number of knots that showed
the best agreement between the WinBUGS model and the
Nelson-Aalen estimate. This resulted in 34 trials with 2 knots
and 3 trials with 1 knot. Knot locations were then tweaked
where necessary to improve the agreement between the Win-
BUGSmodel and theNelson-Aalen estimate and to ensure the
log cumulative hazard from the WinBUGS model fell within
the 95% confidence intervals of the Nelson-Aalen estimate. A
table of knot locations can be found in Appendix B.
Data formatting including the calculation of basis functions
can be conducted in any statistical package. All models were
run in WinBUGS21 version 1.4.3. The Stata suite of com-
mands winbugs27 was used to control all aspects of model fit-
ting in WinBUGS through Stata28 version 14. Example Stata
code for calculating basis functions and running WinBUGS
from Stata along with the WinBUGS model is provided in
Appendix A.
Initially, we considered fixed treatment effect (FTE) mod-
els with random treatment effect (RTE) models considered
where there was evidence of heterogeneity. Final models were
run with 20 000 burn-in and then 20 000 iterations and with 2
sets of initial values. Convergence was checked by examining
the trace and histograms of the posterior distribution. Models
were compared using the deviance information criteria (DIC)
statistic.29,30
3.3 Results of pairwise MA using
the Royston-Parmar method
Initially, we treated the network as 4 separate pairwise
meta-analyses and conducted a one-step MA of each compar-
ison using (2). Figure 2 shows 4 forest plots of log hazard
ratios (LogHR) and 95% credible intervals (CrI). The result-
ing FTEs are presented in Table 1. The treatment effects
were consistent with the treatment effects from a two-stage
pairwise MA using the Cox model. Results of the pairwise
MA suggest CTRT improves overall survival by 19% com-
pared to RT (LogHR=−0.215, 95% CrI: −0.336, −0.086),
CT+S improves overall survival by 36% compared to RT
(LogHR=−0.447, 95% CrI: −0.654, −0.243), and CT+S
also improves overall survival by 36% compared to CT+RT
(LogHR=−0.444, 95% CrI: −0.830, −0.061).
Cochran's Q statistic can be used to assess heterogeneity
within each treatment comparison.31 There was no evidence
of statistical heterogeneity within the RT vs CTRT (P=.625,
Table 1), RT vs CT+S (P=.065), and CT+RT vs CT+S
(P=.939) comparisons while there was some evidence of
statistical heterogeneity in the RT vs CT+RT comparison
(P<.001, also noted in the original publication23). When we
split the RT vs CT+RT comparison into subgroups based on
length of chemotherapy cycles, we found no evidence of het-
erogeneity in the trials with chemotherapy cycles greater than
14 days (P=.263). However, there was evidence of hetero-
geneity in the trials with chemotherapy cycle lengths of 14
days or less (P=.002). Heterogeneity can also be assessed
visually by considering the forest plots in Figure 2. Due to
the presence of heterogeneity in one of the pairwise com-
parisons going forward, we will need to consider RTE NMA
models. There was no evidence globally of non-PH in any of
the treatment comparisons (Table 1, column 4); however, the
Schoenfeld residuals indicate that there may be some trials
in the RT vs CTRT comparison, which are at risk of non-PH
(P=.059, Table 1, column 5). However, we have performed
multiple tests, and this is only borderline significant. More-
over, the global test of nonproportionality in log(t) is far from
significant; therefore (in the light of our discussion at the end
of Section 3.1), we continue under the assumption of PH in
the cervical cancer network.
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FIGURE 2 Pairwise fixed treatment effect meta-analysis for all pairwise comparisons in the cervical cancer network. Top left: RT vs CTRT, top
right: RT vs CT+RT, bottom left: RT vs CT+S, bottom right: CT+RT vs CT+S
TABLE 1 Meta-analysis results using Royston-Parmar models
Comparison FTE* Cochran's Q Global Non-PH Test Schoenfeld Residuals
RT vs CTRT −0.215 (−0.336, −0.086) 12.71, 15 df, P=.625 𝜒2=0.161, 1 df, P=.688 𝜒2=25.64, 16 df, P=.059
RT vs CT+RT −0.191 (−0.375, −0.007) 20.69, 6 df, P=.002 𝜒2=2.522, 1 df, P=.112 𝜒2=10.34, 7 df, P=.170
⩽14 days
RT vs CT+RT 0.227 (0.073, 0.385) 12.34, 10 df, P=.263 𝜒2=0.006, 1 df, P=.944 𝜒2=7.65, 11 df, P=.744
>14 days
RT vs CT+S −0.447 (−0.654, -0.243) 8.85, 4 df, P=.065 𝜒2=0.118, 1 df, P=.731 𝜒2=8.65, 5 df, P=.124
CT+RT vs CT+S −0.444 (−0.830, −0.061) 0.01, 1 df, P=.939 𝜒2=0.164, 1 df, P=.686 𝜒2=0.49, 2 df, P=.783
Abbreviations: CTRT, chemoradiation; CT+RT, neoadjuvant chemotherapy plus radiotherapy; CT+S, neoadjuvant chemotherapy plus surgery; FTE, fixed treatment
effect; RT, radiotherapy; PH, proportional hazard.* Values are log hazard ratios and 95% credible intervals.
4 NETWORK META-ANALYSIS
USING ROYSTON-PARMAR METHOD
4.1 One-step IPD NMA model
for time-to-event data
The one-step NMA model models the log cumulative hazard
individually for each trial with its own spline function (1) and
location of knots. For patient i in trial j in a network of q + 1
treatments, the FTE model takes the following form:
ln{Hj(t|xij)} = sj( ln(ti)) + 𝛽1trt1i + · · · + 𝛽qtrtqi, (6)
where trtqi is a treatment contrast variable. Some care is
needed in defining the treatment contrasts to ensure that they
are in the right direction. This is necessary for the model
to be properly defined. The treatment contrasts are patient
level variables, which can take the value 0, 1, or −1. Where
there are treatment loops in the network, the treatment con-
trasts represent the consistency equations. For example, in a
3-treatment network consisting of treatments A, B, and C,
where 𝜇AB is the treatment effect of treatment B compared
to treatment A, the treatment effect for treatment C com-
pared to treatment B can be calculated as 𝜇BC = 𝜇AC − 𝜇AB.
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This means that only 2 treatment contrast variables (repre-
senting the coefficients of 𝜇AB and 𝜇AC) need defining.
Specifically, in the cervical cancer network where there are
4 treatments (with one 3-treatment loop, Figure 1), we need to
define 3 treatment contrast variables. We chose to define the
treatment contrast variables for RT vs CTRT, RT vs CT+RT,
and RT vs CT+S. In Figure 1, the arrows indicate the direc-
tion of the treatment effects. RT is the reference treatment for
trials comparing RT and CTRT, RT and CT+RT, and RT and
CT+S. For trials comparing CT+RT and CT+S, CT+RT is
the reference treatment and the treatment contrasts need to
reflect this. For patients in a CT+RT vs CT+S trial receiv-
ing CT+S there must be a “−1” for the coefficient of RT
vs CT+RT and a “1” for the coefficient of RT vs CT+S.
For patients in a CT+RT vs CT+S trial receiving CT+RT,
the coefficients of RT vs CT+RT and RT vs CT+S must
both be “0.”
In other words, if trt1i is the treatment contrast variable for
RT vs CTRT, trt2i is the treatment contrast variable for RT vs
CT+RT, and trt3i is the treatment contrast variable for RT vs
CT+S, then
trt1i =
{
1 if patient was randomised to CTRT and is from a trial comparing
RT and CTRT
0 otherwise
trt2i =
⎧⎪⎪⎨⎪⎪⎩
1 if patient was randomised to CT+RT and is from a trial comparing
RT and CT+RT
−1 if patient was randomised to CT+S and is from a trial comparing
CT+RT and CT+S
0 otherwise
trt3i =
{
1 if patient was randomised to CT+S and is from a trial comparing
RT and CT+S or CT+RT and CT+S
0 otherwise.
The corresponding RTE model takes the form:
ln{Hj(t|xij)} = sj( ln(ti)) + 𝛽1jtrt1i + · · · + 𝛽qjtrtqi (7)(
𝛽1
⋮
𝛽q
)
∼ MVN(𝜇,T),
where T is the unstructured inverse between-study
variance-covariance matrix. In this paper, we use an unstruc-
tured covariance matrix because the cervical cancer network
is a simple network with lots of data, which can support
the estimation of an unstructured covariance matrix. Unless
there is a strong a priori reason for a common heterogene-
ity variance, this is more plausible. However, when there
are fewer trials, a simpler approach such as the Higgins
and Whitehead32 approach to estimating the between-study
variance-covariance matrix could also be used. This approach
requires the estimation of only one parameter, and so is
particularly popular when there is relatively little information
available to estimate an unstructured covariance matrix.
4.1.1 Global test for non-PHs
We now detail 2 approaches for testing the assumption of PH.
Firstly, a network test for non-PH can be conducted by includ-
ing an interaction between treatment and ln(time) in a FTE or
RTE model:
ln{Hj(t|xij)} = sj( ln(ti)) + 𝛽1jtrt1i + · · · + 𝛽qjtrtqi
+ 𝛽(q+1)jtrt1i (ln(ti)) + · · · + 𝛽(2q)jtrtqi (ln(ti)) ,
(8)
As before (Section 3.1.1), the derivative (3) of the log cumu-
lative hazard must also be updated. Annotated model code
based on the cervical cancer network in Figure 1 is provided
in Appendix A. After fitting the model, we can perform an
approximate global Wald test on the treatment-ln(time) inter-
action terms to determine whether there is, on average, any
evidence of non-PH within the network. The null hypothesis
states that the treatment-ln(time) interactions are simultane-
ously equal to zero so that there is no evidence of non-PH in
the network. Details for conducting a Wald test can be found
in Appendix C.
Our second approach that gives more insight into which
trials are driving any nonproportionality is to allow the inter-
action terms to vary by trial. We can extend the FTE model
(6) in this way:
ln{Hj(t|xij)} = sj( ln(ti)) + 𝛽1jtrt1i + · · · + 𝛽qjtrtqi
+
(
𝛽(q+1)j + uj
)
trt1i (ln(ti)) + …
+
(
𝛽(2q)j + uj
)
trtqi (ln(ti))
(9)
uj ∼ N
(
0, 𝜎2u
)
,
Annotated model code based on the cervical cancer net-
work in Figure 1 is provided in Appendix A. As before, an
approximate global Wald test of the fixed treatment-ln(time)
and variance parameters can then be conducted to determine
whether there is any evidence of non-PH within the network.
By allowing a random effect of treatment-ln(time) by trial,
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we obtain a shrinkage estimate of the departures from PH in
each trial. We can display this graphically by plotting the val-
ues of the uj parameters along with an interval of uj±1.96sdj,
where sdj is the standard deviation of uj for trial j.
Non-PH in some or all of the trials can be accommodated
by re-fitting (8) or (9) and restricting the treatment-ln(time)
interaction terms to apply only to the trials exhibiting evi-
dence of non-PH. The timescale could then be divided up and
the log hazard ratios assessed within each time interval. Alter-
natively, a spline that allows the treatment effect to vary over
time could be added.
4.2 Assessment of inconsistency
A network is considered to be consistent when the treatment
effect estimates from the direct comparisons are in agreement
with the treatment effect estimates from the indirect compar-
isons. Therefore, inconsistency occurs within a treatment loop
when the indirect evidence is not in agreement with the direct
evidence. As a result, inconsistency is a property of a treat-
ment loop not of a treatment comparison.33 This is different
to heterogeneity, which can be defined as the amount of dis-
agreement between trial-specific treatment effects amongst
trials comparing the same treatments.34
To assess inconsistency, we introduced a fixed effect incon-
sistency parameter to (6) following the method of Lu and
Ades.11 This allowed us to obtain estimates of the direct and
indirect information for each comparison within the treatment
loop formed by RT, CT+RT, and CT+S. In a network con-
taining one 3-treatment loop between treatments A, B, and C,
let 𝜔ABC represent the inconsistency parameter for this loop.
We can then extend (6) in this way:
ln{Hj(t|xij)} = sj( ln(ti)) + 𝛽1trt1ij
+ 𝛽2trt2ij − 𝜔ABCtrt1ijtrt2ij,
(10)
An inconsistency parameter can be added to the RTE model
in the same way. In passing, the inclusion of an inconsis-
tency parameter allows us to test for inconsistency between
two-arm trials only as by definition multiarm trials are inter-
nally consistent. Note, we only need to fit one model with the
inconsistency parameter to separate out the direct and indirect
evidence for all trials in the loop. The cervical cancer network
contains one treatment loop so only one inconsistency param-
eter was included in the model. See annotated model code in
Appendix A for cervical cancer network shown in Figure 1.
As noted in Section 4.4, similar results could be obtained
by back-calculation. For more complex networks, our models
could readily be extended to incorporate node-splitting.35
4.3 Inconsistency and heterogeneity
We briefly consider how to proceed if there is some evidence
of heterogeneity (when we do not model inconsistency) and
inconsistency (when we do not model heterogeneity, ie, in the
FTE model).
First, suppose there is no funnel plot asymmetry in the pair-
wise MAs within the network so that the FTE point estimate
and RTE point estimate are virtually identical. In this case, if
there is inconsistency, then the extent of inconsistency will be
the same in both the FTE and RTE model. However, if there
is heterogeneity, then the standard error of the point estimate
will be (appropriately) larger in the RTE than the FTE esti-
mate. This will reduce the power to detect inconsistency in
the RTE model.
Alongside, this is the fact that even in the FTE model,
the inconsistency test has relatively low power. Therefore, in
practice, if we find inconsistency in the FTE model, but there
is also heterogeneity, then moving to a RTE model may mean
the inconsistency is no longer detectable.
In practice, we would lean to the following approach: (1) fit
the FTE model, test for inconsistency, and include an incon-
sistency parameter if needed; (2) fit the RTE model if needed
(retain the inconsistency parameter if it was needed in the
FTE model); (3) if the RTE model is needed, explore whether
the conclusions are sensitive to including the inconsistency
parameter (regardless of its formal significance); if they are,
we would prefer to retain it. This approach could usefully be
complemented by an initial assessment of heterogeneity in
pairwise MA. If inconsistency is present, results should not
be used for clinical inference without resolving the cause of
the underlying inconsistency/heterogeneity.
4.4 Assessment of heterogeneity
Heterogeneity should be assessed within each pairwise com-
parison before an NMA model is fitted, both visually through
the use of forest plots and using formal statistical tests. For
the cervical cancer network, this was reported in Section 3.3.
Once an FTE NMA model is fitted, Cochran's Q statistic can
be used to assess heterogeneity within the network. The over-
all Q statistic from the FTE NMA model can be decomposed
into within-design heterogeneity (Qhet) and between-design
heterogeneity representing inconsistency between designs
(Qinc). Let ?̂?ij be the treatment effect estimate for trial i of
design j, ?̂?j be the treatment effect from the direct evidence for
design j only, and ?̂?Nj be the network estimate of the treatment
effect for design j, then
Q =
∑
j
∑
i
{
?̂?ij − ?̂?Nj
?̂?ij
}2
Qinc =
∑
j
{
?̂?j − ?̂?Nj
?̂?j
}2
Qhet =
∑
j
∑
i
{
?̂?ij − ?̂?j
?̂?ij
}2
,
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with Q = Qinc+Qhet. A corresponding matrix decomposition
holds for multiarm trials. An alternative method of assessing
heterogeneity would be to present values of 𝜏2.
4.5 Ranking of treatments
To rank the treatments, we took each iteration in turn and
ranked the treatments from most effective to least effective.
The most effective treatment had the smallest log hazard
ratio value, and the least effective treatment had the largest
log hazard ratio value. We then counted how many times
each treatment was considered the first, second, third, fourth,
and fifth most effective treatment and expressed these as
percentages.
4.6 Prior distributions
In the FTE model, parameters representing the spline func-
tion for the baseline log cumulative hazard function, treatment
effects, inconsistency parameters, and treatment-ln(time)
interactions were fitted with noninformative normal prior dis-
tributions (𝛾 ∼ N(0, 10000), 𝛽 ∼ N(0, 1000), 𝜔 ∼ N(0, 10)).
For model (9), 𝜎u ∼ N(0, 1000), which was restricted to
be positive.
In the RTE model 𝛽 ∼ MVN(𝜇,T) with 𝜇 ∼ (0, 𝜎) and
𝜎 a matrix with 0.001 on the diagonal and 0 elsewhere. The
prior distribution for T is an inverse Wishart distribution T ∼
IW(V, k) where V is a pxp scale matrix with the degrees of
freedom, k(⩾ p), as small as possible to reflect vague prior
knowledge. Prior distributions for all other parameters remain
the same as for the FTE model.
5 RESULTS
Here, we present the results of using the one-step IPD
Royston-Parmar approach for NMA with the cervical can-
cer dataset introduced in Section 2. Parameter estimates are
presented as log hazard ratios with 95% credible intervals for
the posterior mean. A log hazard ratio of 0 indicates a null
effect. A log hazard ratio less than zero indicates a beneficial
effect relative to the reference treatment. In Section 3.3, we
identified heterogeneity in the RT vs CT+RT comparison and
presented results with the trials split by chemotherapy cycle
length. In this section, the NMAmodel includes an additional
parameter for cycle length, which, through the use of an indi-
cator variable, can only contribute to the hazard in trials with
long chemotherapy cycles. By doing this, we treat CT+RT
short cycles and CT+RT long cycles as 2 separate treatments,
so explaining this source of heterogeneity. Due to the pres-
ence of heterogeneity in one of the pairwise comparisons, we
will consider both FTE and RTEmodels. The RTEmodel will
take into account statistical heterogeneity.
Prior to conducting the NMA, to check that an appropriate
spline model was chosen for each trial, the log cumulative
hazard was fitted individually for each trial in WinBUGS and
then plotted against the nonparametric Nelson-Aalen estimate
to assess the fit of the model to the data. All trials, except
3, used spline models with 2 interior knots, the remaining 3
trials used 1 interior knot.
We start by fitting FTE and RTE models in Section 5.1 and
assessing the assumptions of PH (Section 5.1.1) and inconsis-
tency (Section 5.2). In Section 5.3, we assess the network for
any evidence of heterogeneity before ranking the treatments
in order of effectiveness (Section 5.4).
5.1 Model results
Figure 3 shows the direct, indirect, and network treatment
effects for the cervical cancer network. The direct and indi-
rect treatment effects are estimated through the inclusion of
an inconsistency parameter as described in Section 4.2. We
see that in this network, we have limited indirect evidence
so that our network treatment effects are fairly close to the
FIGURE 3 Cervical cancer results. Left: fixed treatment effect, right: random treatment effect
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TABLE 2 Results of the fixed treatment effect (FTE) and random treatment effect (RTE) NMA models and DIC
FTE RTE
Treatment Effects Model Fit Treatment Effects Model Fit
RT 0 pD 138.6 RT 0 pD 152.2
CTRT −0.211 (−0.337, −0.087) D̄ 12182.9 CTRT −0.207 (−0.374, −0.046) D̄ 12163.6
CT+RT 0.028 (-0.164, 0.220) DIC 12321.5 CT+RT 0.086 (-0.229, 0.428) DIC 12315.8
⩽14 days ⩽14 days
CT+RT 0.223 (0.065, 0.380) CT+RT 0.273 (0.031, 0.538)
>14 days >14 days
CT+S −0.396 (-0.611, −0.185) CT+S −0.333 (−0.701, 0.011)
Abbreviations: CTRT, chemoradiation; CT+RT, neoadjuvant chemotherapy plus radiotherapy; CT+S, neoadjuvant chemotherapy plus surgery;
DIC, deviance information criteria; NMA, network meta-analysis; RT, radiotherapy.Results for treatment effects are log hazard ratios (95%
credible intervals).
direct effects. Assuming consistency, the network treatment
effect for CTRT compared to RT is statistically significant
in both the FTE and RTE model with the RTE model sug-
gesting an 18% improvement in overall survival with CTRT
(LogHR=−0.207, 95% CrI: −0.374, −0.046, Table 2). The
results of the FTE and RTE models are consistent with each
other. The DIC provides only weak evidence in favour of the
RTE model (difference in DIC of 5, Table 2); however, the
presence of heterogeneity suggests that the RTE model is the
best choice.
5.1.1 Global test for non-PHs
Here, we present the results from our 2 methods for assess-
ing the assumption of PH. From the first approach, the
Wald test for non-PH from the RTE model with random
treatment-ln(time) interactions gave 𝜒2 = 0.324 on 3 degrees
of freedom (P=.955) suggesting that, on average, there is no
evidence of non-PH within the network.
In the second approach, when we allow the treatment-
ln(time) interaction parameters to vary by trial, the Wald test
for the RTE model gave 𝜒2 = 0.663 on 4 degrees of freedom
(P=.956) suggesting that, on average, there is no evidence of
non-PH within the network. Figure 4 displays the amount of
variation in the treatment-ln(time) interactions for each trial
from the RTE model with random treatment-ln(time) inter-
actions. There is little variation between trials supporting the
conclusion, from the Wald test, that there is no evidence of
non-PH within the network.
5.2 Assessment of inconsistency
To assess inconsistency and to obtain estimates of the direct
and indirect information for each comparison within the treat-
ment loop, a fixed effect inconsistency parameter was intro-
duced to the treatment loop formed by RT, CT+RT, and
CT+S, as described in Section 4.2 and (10). From the RTE
model, the inconsistency parameter was estimated as −0.484
(95% CrI: −1.314, 0.354). In Figure 3, we separate out the
direct and indirect evidence for each treatment comparison
and display these alongside the network estimates. It can be
seen that the direct and indirect treatment effects differ from
each other with the network estimates balancing out these 2
sources of information. Therefore, the cervical cancer net-
work has a suggestion of inconsistency and the model results
should be cautiously interpreted.
5.3 Assessment of heterogeneity
From the FTE model, there was evidence of statistically sig-
nificant heterogeneity in the whole network (Q=56.86 on 35
df, P=.011) and between designs (Q=10.32, 2 df, P=.006).
There was also some evidence of heterogeneity within each
design (Q=46.21 on 33 df, P=.063), which was largely driven
by the heterogeneity within the RT vs CT+RT (chemother-
apy cycles less than 14 days) comparison (Q=16.74, 6 df,
P=.010), as previously identified in Figure 2. The heterogene-
ity between designs was driven by the Sardi 96 trial.36 Sensi-
tivity analysis excluding the Sardi 96 trial reduced the overall
Q to borderline significance (Q=47.98 on 33 df, P=.044) and
removed the inconsistency between designs (Q=2.53 on 2 df,
P=.282). Treatment effect estimates for RT vs CT+RT with
chemotherapy cycles less than or equal to 14 days and RT vs
CT+Swere slightly reduced in both the FTE and RTEmodels
and remained consistent with each other.
5.4 Ranking of treatments
The ranking of treatments in order of most effective to least
effective is consistent between the FTE and RTE models. In
both models, CT+S comes out as the most effective treat-
ment, CTRT the second most effective treatment, CT+RT
with chemotherapy cycles less than or equal to 14 days the
third most effective treatment, RT the fourth most effective
treatment and CT+RT with chemotherapy cycles greater than
14 days as the least effective treatment (Figure 5).
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FIGURE 4 Variation in treatment-ln(time) interactions for assessment of nonproportional hazard in random treatment effect network
meta-analysis model. Top left: RT vs CTRT, top right: RT vs CT+RT, bottom left: RT vs CT+S, bottom right: CT+RT vs CT+S
FIGURE 5 Treatment ranks from fixed treatment effect NMA model (left) and random treatment effect NMA model (right). NMA, network
meta-analysis
6 DISCUSSION
The literature for conducting NMA with time-to-event data
is rather sparse. This paper extends work by Royston and
Parmar20 to the NMA setting, showing that Royston-Parmar
models, fitted in WinBUGS, provide a flexible, practical
approach for Bayesian NMA with time-to-event data. They
avoid the computational issues that beset a Bayesian imple-
mentation of the Cox model, which (see Section 1) we found
computationally intractable for our cervical cancer network.
An advantage of this approach is that, if we wish, we can read-
ily obtain an estimate of the baseline hazard, pooled across
trials. To do this, we make the coefficients for the RCS ran-
dom across trials (this requires the knots to be in the same
position for all studies). The Bayesian approach also provides
a computationally straightforward and inferentially natural
framework for ranking treatments.
The proposed approach naturally allows the inclusion of
patient level covariates. The Bayesian aspect means we can
readily allow covariates to have random coefficients, avoid-
ing the numerical integration needed to maximize the cor-
responding likelihoods. This in turn naturally allows us to
test for, and accommodate, departures from proportional-
ity in some or all of the studies, by including appropriate
treatment-ln(time) interactions. Making these random (as in
Equation 9) gives us a Bayesian shrinkage estimate of the
extent of each study's departure from PH (Figure 4). The
shrinkage reduces the likelihood of overinterpreting apparent
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departures from proportionality in smaller studies. Where
proportionality is not appropriate, it naturally allows for—for
example—effect estimation using restricted mean survival
time as an estimate of treatment efficacy,37 which has so far
been considered only in the MA setting.38
Network meta-analysis combines direct and indirect evi-
dence. Since the latter requires much stronger assumptions,
it is sensible to check that they are consistent. We illustrated
how this may be done using the model-based version of the
method proposed by Bucher.33 One inconsistency parame-
ter is required for each treatment loop within a network, and
we simply refit the NMA model with all these parameters
included. This allows us to separate the direct and indirect
contributions to each treatment effect (Figure 3). We believe
these should always be presented, because readers should
be aware of the extent to which conclusions rest on indirect
evidence, with its attendant additional assumptions.
Besides the Cox model (discussed in Section 1), another
option is a piecewise constant hazard model, also referred to
as a piecewise Poisson model. With this model, the dataset
needs to be expanded for each piecewise constant hazard.
Thus, this approach is affected by the same issue as the Cox
model, especially if a large number of intervals of piecewise
constant hazard are required. Crowther14 suggested alleviat-
ing the computational burden this causes by collapsing across
covariate patterns; however, this is not ideal and not pos-
sible with continuous covariates. By contrast, as our code
shows, the Royston-Parmar model avoids these issues. Nev-
ertheless, there is a price to be paid in computational time.
Where the same model can be fitted using a generic Bayesian
program such as WinBUGS, and by maximum likelihood,
WinBUGS will typically be slower than the corresponding,
model specific, maximum likelihood software. However, this
drawback is far from prohibitive. On a laptop with an Intel
Core i7-3540M processor with 4Gb of RAM, Model (6) took
0.045 second per update, so a burn in of 1000 updates fol-
lowed by 4000 further updates to estimate the posterior takes
less than 4 minutes.
It is also possible to conduct an IPD NMA using the
Royston-Parmar model as a two-step approach and to fit the
Royston-Parmarmodel in the frequentist setting. In a two-step
approach, the Royston-Parmar model is fitted individually to
each trial and then study estimates of the log hazard ratio and
its standard error can be pooled together in the second step.
In the same way, a two-step approach could be used with the
Cox model. Indeed, we found the results of the one-step FTE
Royston-ParmarMAmodel fitted in the Bayesian settingwere
consistent with the two-step approach using the Cox model
fitted in the frequentist setting for all 4 treatment comparisons
in the cervical cancer network.
In the frequentist setting, the Royston-Parmar model can
be fitted in Stata using the stpm224 command and in R
using the flexsurv39 package. Two-step IPD MA, using the
Royston-Parmarmodel or the Coxmodel, can be conducted in
Stata using the ipdmetan40 command. A random effects MA
using the Royston-Parmar model could be fitted in the fre-
quentist setting using the Stata command stmixed8 or using
SAS PROC NLMIXED. However, both rely on numerical
integration, which—as discussed in the Introduction—has
some drawbacks.
This paper provides a base for further extensions. Work
is currently ongoing to extend the Royston-Parmar model
to include covariates and treatment-covariate interactions. A
one-stage Bayesian approach to fitting these models has many
benefits as the models increase in complexity. This includes
the ability to handle missing patient level covariates as part of
the modelling. However, estimating treatment-covariate inter-
actions in an NMA needs to be done with care. We need to
decide whether to model the covariate with trial specific or
arm specific coefficients and need to separate out the within
study and across network information, which is at risk of
ecological bias.41
The NMA literature contains many examples when we
wish to synthesize IPD and aggregate data. For example,
Donegan42 showed how to combine IPD and aggregate data
for dichotomous endpoints. Saramago43 showed how to do
this in an FTE NMA model under the assumption that event
times are Weibull distributed. In both cases, covariates can be
included, with patient level values used for IPD trials and trial
mean values used for aggregate data trials; however, PH can
only be assessed in IPD trials. Synthesis of IPD and aggre-
gate data is particularly natural in the Bayesian framework,
where random effects can be naturally included to accom-
modate the inevitable heterogeneity. Therefore, the approach
proposed here provides a flexible method of synthesising IPD
and aggregate data for time-to-event outcomes, which avoids
distributional assumptions.
We fitted our RTE models using an inverse Wishart prior
for the between-study variance-covariance matrix. It has been
highlighted by Wei and Burke that a Wishart prior may
not be the most appropriate choice of prior distribution.44,45
However, in the NMA setting where we have multiple
treatments, there are few alternatives. A Wishart prior can
become influential in the estimation of the between-study
variance-covariancematrix and can lead to the overestimation
of heterogeneity parameters particularly when the true hetero-
geneity is close to zero.44 Conducting NMA in the Bayesian
framework allows for the possibility of including empiri-
cal evidence in the prior distributions, which could result
in a more realistic prior distribution for the between-study
variance-covariance matrix particularly when small numbers
of trials are available.46
Network meta-analysis models play a key role in pol-
icy decisions. Yet they are complex, both in terms of
assumptions and modelling. We have found the following
diagnostics useful:
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1. using the shrinkage estimator to test for PH: the shrink-
age reduces the likelihood of overinterpreting departures
from PH;
2. graphically comparing theNMA spline estimate of the log
cumulative hazard with the Nelson-Aalen nonparametric
estimate;
3. fitting a version of the model with an inconsistency
parameter in each of the network loops, and using the
results to present the direct, indirect, and combined treat-
ment estimates;
4. using the Q statistics to identify heterogeneity. This
may be addressed by including random effects in some
trial comparisons or by conducting sensitivity analysis
in which trials whose treatment effects diverge from the
norm are excluded.
In summary, Bayesian NMA of IPD offers many practi-
cal advantages but is computationally problematic with the
Cox PH model, even with moderate size datasets. We have
shown that the Royston-Parmar model provides a flexible,
computationally practical, way forward which has the poten-
tial to extend to accommodate issues such as non-PH which
are increasingly arising in oncology studies.
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